Corona Remedies Limited IPO

Mainboard

Pharmaceuticals

Listed On: Dec 15, 2025 at ₹ 1470.0(NSE)

₹ 14868 /14 Shares

Check Allotment

08 Dec, 2025

Open Date

10 Dec, 2025

Close Date

11 Dec, 2025

Allotment Date

15 Dec, 2025

Listing Date

Price Summary

Last Closing

1,504.70 (41.69%)

52 Week High

1,524.00

52 Week Low

1,336.60

Last Update

16-Jan-2026 3:30 PM

Expected Premium

+ ₹300-305 (28.25%)

*Expected Premium provided in this app is derived from market rumors. It is not a guaranteed indicator of the actual listing price and should be interpreted with caution.

Corona Remedies IPO Live Subscription Details

View Subscription Details

QIB 293.80x

Retail 30.29x

NIIs 220.18x

BHNI 246.67x

SHNI 167.20x

Retail 30.29x

EMP 15.56x

Total 144.49x

Last updated: 10 Dec 2025, 05:57 PM

Corona Remedies IPO Issue Details

Issue Price ₹1008-1062 per equity share
Face Value ₹10 Per Equity Share
Total Issue Size 61,71,101 shares(aggregating up to ₹655.37 crore)
Offer For Sale 61,71,101 shares(aggregating up to ₹655.37 crore)
Listing at BSE, NSE
List Price 1470.0(NSE)
Listing Date 2025-12-15
Lead Manager JM Financial Ltd
IIFL Capital Services Ltd
Kotak Mahindra Capital Co.Ltd
Kotak Mahindra Capital Co.Ltd.
Registrar Bigshare Services Pvt Ltd

Market Lot Size

Investors can bid for a minimum of 14 shares and in multiples thereof. The following table depicts the minimum and maximum investment by Retail Investors and HNI in terms of shares and amount.

Application	Lots	Shares	Amount
Retail (min)	1	14	₹14,868
Retail(max)	13	182	₹1,93,284
SHNI(min)	14	196	₹2,08,152
SHNI(max)	67	938	₹9,96,156
BHNI(min)	68	952	₹10,11,024

Corona Remedies IPO Reservation

Corona Remedies IPO offers total 6171101 shares. Out of which 1221729 (19.8%) allocated to QIB, 916960 (14.86%) allocated to NII,2139573 (10%) allocated to RII, 58036 (0.94%) allocated to employees and 1834804 (29.73%) allocated to Anchor investors.

Investor Category	Shares Offered	Maximum Allottees
Anchor Investor Shares Offered	1834804 (29.73%)
QIB Shares Offered	1221729 (19.8%)
NII (HNI) Shares Offered	916960 (14.86%)
bNII > ₹10L	611307 (10%)
sNII < ₹10L	305653 (5%)
Retail Shares Offered	2139573 (10%)
Employee Shares Offered	58036 (0.94%)
Total Shares Offered	6171101 (100%)

Corona Remedies IPO Documents

DRHP

RHP

ANCHOR

Corona Remedies IPO Details

Corona Remedies IPO is a book-built issue of ₹655.37 crores, The total issue size is ₹655.37 crores. The IPO of Corona Remedies is priced at ₹1008-1062 per equity share, which has a face value of ₹10 Per Equity Share each, IPO bidding starts from Dec 8, 2025 and ends on Dec 10, 2025. The allotment for Corona Remedies IPO will be finalized on Dec 11, 2025. Corona Remedies IPO will be listed on BSE, NSE, with a tentative listing date fixed as Dec 15, 2025. The company shall list its equity shares on the BSE, NSE. Bigshare Services Pvt Ltd is the registrar of the issue.

Retail investors can bid for a minimum of 14 shares, extendable to 14,868. S-HNIs will be able to bid for 196 shares at ₹2,08,152, while B-HNIs can also apply for a bid of 952 shares at ₹10,11,024. The book-running lead manager for the IPO is/are JM Financial Ltd, IIFL Capital Services Ltd, Kotak Mahindra Capital Co.Ltd, Kotak Mahindra Capital Co.Ltd..

The total issue ₹655.37 crore and having Offer for Sale (OFS) of 61,71,101 shares to mop up ₹655.37 crore.

The Corona Remedies IPO sets its price band at 1008-1062 for each share. A single application for Corona Remedies Limited IPO must contain at least 14 shares. Sentiment investors need to invest a minimum of 14 through their retail account. For investors to prevent oversubscription issues, they should submit bids at the cutoff price, which estimates about ₹14,868 In order to participate in the sNII, investors must purchase at least 14 lots of 196 shares for ₹2,08,152, while the bNII requires 68 lots of 952 shares for an investment of ₹10,11,024.

As on	QIB	NII bNII sNII	Retail	Total
Shares Offered / Reserved	12,21,729	9,16,960 6,11,307 3,05,653	21,39,573	43,36,298
Day 1 08-12-25 05:00 PM	0.00 x	0.84 x 0.53 x 1.45 x	0.93 x	0.66 x
Day 2 09-12-25 05:00 PM	1.76 x	28.32 x 29.02 x 26.92 x	6.81 x	9.90 x
Day 3 10-12-25 05:00 PM	293.80 x	220.18 x 246.67 x 167.20 x	30.29 x	144.49 x

Total No of Applications

42,38,858

Subscription on the basis of Applications

Retail:24.82x BHNI:49.77x SHNI:160.35x

Corona Remedies Valuations

EPS Pre IPO ₹24.43/-

EPS Post IPO ₹30.21/-

P/E Pre IPO 43.47

P/E Post IPO 35.15

ROE 27.50%

ROCE 41.32%

Debt/Equity 0.10

RoNW 24.65%

PAT Margin 12.49%

Price to Book Value 10.71

Market Cap. 6495.20 Cr.

Corona Remedies Company Financials

In Crs.

In Cr.

	30-Jun-25	31-Mar-25	31-Mar-24	31-Mar-23
Assets	1012.38	929.86	830.58	595.02
Revenue	348.56	1202.35	1020.93	891.10
Profit After Tax	46.20	149.43	90.50	84.93
Net Worth	607.02	606.34	480.41	408.52
Reserves & Surplus	545.86	545.18	419.25	347.36
Total Borrowing	106.65	62.70	134.14	2.33

About Corona Remedies Company

Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women's healthcare, cardiology, pain management, urology, and other therapeutic areas.

The diversified portfolio of the company as of December 2024 comprises 67 brands across therapeutic areas such as women's healthcare, cardio-diabeto, pain management, urology, and multispecialty pharmaceuticals, including vitamins/minerals/nutrition, gastrointestinal, and respiratory.The company has a pan-India marketing and distribution network with 2,598 medical representatives in 22 states, enabling effective engagement with healthcare professionals and hospitals, thus consolidating its presence in the IPM and ensuring deep penetration in therapeutic areas.

Presently, the company owns two manufacturing facilities located in the states of Gujarat.

As of December 31, 2024, the company had 88 R&D employees.

Corona Remedies - Promoter(s)

Dr. Kirtikumar Laxmidas Mehta

Niravkumar Kirtikumar Mehta

Ankur Kirtikumar Mehta

Pre Issue Share Holding : 72.50%

Post Issue Share Holding : N/A%

Corona Remedies IPO - Issue Objectives

Corona Remedies IPO - Anchor Investors

Corona Remedies raises nearly Rs 195 crore from 15 anchor investors.

Of the total anchor allotment, 13.59 lakh shares worth Rs 144.4 crore were allotted to 11 domestic mutual funds including SBI Mutual Fund, ICICI Prudential MF, Kotak Mahindra AMC, Axis Mutual Fund, Mirae Asset, Aditya Birla Sun Life AMC, Invesco, DSP MF, Franklin India and Tata MF that have applied through their total of 13 schemes.
The other investors that participated in the anchor book included SBI Life Insurance, Ashoka India, FSSA Indian Subcontinent Fund, and IIFL Asset Management.

Corona Remedies IPO - Peers Comparison

	P/B Ratio	P/E Ratio	RoNW	Revenue(in Cr.)
Corona Remedies	N/A	N/A	24.6%	1196
Abbott India	N/A	45.1	33.4%	6409
Alkem Lab	N/A	31.3	18.0%	12964
Eris Life	N/A	61.8	12.2%	2893
Glaxosmithkline	N/A	46.8	47.5%	3749
J B Chemicals	N/A	42.6	19.2%	3917
Mankind	N/A	45.7	13.8%	12207
Pfizer	N/A	29.6	18.2%	2281
Sanofi	N/A	24.4	48.0%	2013
Torrent	N/A	65.9	25.1%	11516

Strength

Strong Market Growth Leadership: The second-fastest-growing company among the top 30 pharma players, MAT 2022–2025, is better positioned to capture India’s growing pharma demand.

Diversified and Scalable Product Portfolio: Proven capability to build multiple 'engine brands' across key therapies, including women's health, cardio-diabetic, pain, and urology, to drive sustainable long-term growth.

Robust Pan-India Sales Network: Wide national sales and marketing network with a focus on specialist doctors and mid-income patients enable higher prescription growth than the overall market.

Weakness

High Dependence on Few Therapy Areas: Over 60% of its revenue is derived from women's health, cardio-diabetic, and pain management. Any underperformance or increasing competition in these categories may hurt growth.

Concentration in Limited Engine Brands: 27 key “engine brands” provide over 70% of the domestic sales; any decline in flagship brands such as B-29 or Myoril would materially impact the performance.

High Dependence on Indian Market: Over 96% of the revenue is garnered from India, so weak domestic demand or sluggish international expansion will have an adverse effect on financial stability.

Contact Details

Corona Remedies

CORONA House, C – Mondeal Business Park, Near Gurudwara S. G. Highway, Thaltej, Ahmedabad, Gujarat, 380059

+91 79 4023 3000

complianceofficer@coronaremedies.com

https://www.coronaremedies.com/

Registrar Contact Details

Bigshare Services Pvt Ltd

+91-22-6263 8200

ipo@bigshareonline.com

https://ipo.bigshareonline.com/ipo_status.html

Corona Remedies IPO - FAQs

Ans. Corona Remedies Limited IPO is a Mainboard IPO. The issue is priced at ₹1008-1062 per equity share. The minimum order quantity is 14 Shares. The IPO opens on Dec 8, 2025, and closes on Dec 10, 2025. Bigshare Services Pvt Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.

Ans. The Corona Remedies Limited IPO opens on Dec 8, 2025 and closes on Dec 10, 2025.

Ans. You can track the real-time subscription numbers using the links below:

Ans. The size of Corona Remedies Limited IPO is Offer For Sale : 61,71,101 shares(aggregating up to ₹655.37 Cr).

Ans. The Corona Remedies Limited IPO price band is set between ₹1008-1062 per equity share.

Ans. To apply for Corona Remedies Limited IPO, follow the steps given below:

- Open the IPO Ji App or Website
- Find Corona Remedies Limited IPO in the List of IPOs
- Press Apply Button
- Select Your Demat Account
- Select Your Shares Quantity and Submit
- Track Your IPO Status

Ans. The share allotment date of Corona Remedies Limited IPO is Dec 11, 2025.

Ans. The Corona Remedies Limited IPO will be listed on Dec 15, 2025.

Ans. Follow the steps to check the Corona Remedies Limited IPO allotment status online.